Jasper Therapeutics, Inc.JSPRNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank100
5Y CAGR+237.7%
Year-over-Year Change
Year-over-year operating income growth rate
5Y CAGR
+237.7%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
439.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 29.21% |
| Q2 2025 | -24.19% |
| Q1 2025 | 13.77% |
| Q4 2024 | -27.13% |
| Q3 2024 | -24.36% |
| Q2 2024 | -6.11% |
| Q1 2024 | 14.97% |
| Q4 2023 | 8.45% |
| Q3 2023 | -8.61% |
| Q2 2023 | -27.82% |
| Q1 2023 | -1.45% |
| Q4 2022 | -8.18% |
| Q3 2022 | -6.23% |
| Q2 2022 | 6.38% |
| Q1 2022 | -5.76% |
| Q4 2021 | -19.87% |
| Q3 2021 | -19.73% |
| Q2 2021 | -34.60% |
| Q1 2021 | -4.97% |
| Q4 2020 | 0.83% |
| Q3 2020 | 0.07% |
| Q2 2020 | -122.26% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |